D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment

Yalcin A. D., Celik B., GÜMÜŞLÜ S.

EXPERT OPINION ON BIOLOGICAL THERAPY, vol.14, no.3, pp.283-286, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14 Issue: 3
  • Publication Date: 2014
  • Doi Number: 10.1517/14712598.2014.875525
  • Journal Name: EXPERT OPINION ON BIOLOGICAL THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.283-286
  • Keywords: anti-immunoglobulin E, antithrombin III, chronic urticaria, d-dimer, factor V Leiden and prothrombin G20210A mutation, omalizumab, protein C, severe persistent allergic asthma
  • Akdeniz University Affiliated: Yes

Abstract

Background: D-dimer (DD), a fibrin degradation product formed during the lysis of a thrombus, is also detected in high levels in patients with active chronic urticaria (CU). Severe persistent allergic asthma (SPA) is associated with a procoagulant state in the bronchoalveolar space, further aggravated by impaired local activities of the anticoagulant protein C/protein S, antithrombin III system and fibrinolysis. This was demonstrated as massive fibrin depositions found in the alveoli of a SPA patient who died from a SPA attack and who did not respond to treatment.